Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
Rhea-AI Summary
Vivos Therapeutics (NASDAQ: VVOS) agreed with senior lender Streeterville Capital to exchange up to $4.5 million of debt into perpetual, nonconvertible preferred stock and common shares. The exchange, contingent on qualifying equity financings, is intended to bolster stockholders’ equity, support Nasdaq listing compliance, and reduce debt service.
Streeterville committed to suspend debt repayment calls for 90 days and sales of Vivos securities for 60 days after the exchange becomes effective, which is expected to assist cash flow and liquidity.
Positive
- Binding agreement to exchange up to $4.5 million of senior debt into equity
- Streeterville to suspend debt repayment calls for 90 days after effectiveness
- Streeterville to suspend sales of company securities for 60 days
- Actions intended to improve stockholders’ equity for Nasdaq listing compliance
- Expected reduction in debt service obligations and support for liquidity
Negative
- Debt-to-equity exchange contingent on qualifying equity financings being completed
- Company notes no assurance that required financings or exchanges will occur
- Potential shareholder dilution from new preferred and common stock plus equity raise
News Market Reaction – VVOS
In the Jun 5 session, VVOS gained 24.84%, reflecting a significant positive market reaction. Argus tracked a peak move of +63.9% during that session. Argus tracked a trough of -7.3% from its starting point during tracking. Our momentum scanner triggered 47 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 238.8x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 20 | Q1 2026 earnings | Negative | -0.9% | Revenue growth but wider net loss and continuing equity deficit. |
| Apr 15 | FY 2025 earnings | Negative | -25.9% | Higher revenue alongside sharply wider losses and negative equity. |
| Apr 15 | Results scheduling | Neutral | +8.9% | Announcement of timing for full-year 2025 results and conference call. |
| Apr 7 | Private placement | Neutral | -5.3% | Closed $2.25M financing with warrants and prior bridge note conversion. |
| Mar 26 | Network expansion | Positive | +4.4% | Insurer in‑network status and planned $4.0M annualized cost savings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often centered on financings, growing revenue, and balance sheet strain, with generally negative reactions to full financials but more mixed responses to operational updates and scheduling announcements.
Over recent months, Vivos has combined growth with financial strain. Full-year 2025 results on April 15, 2026 showed revenue rising to $17.5M but losses widening and equity turning negative, prompting a steep -25.85% move. Subsequent Q1 2026 results on May 20, 2026 reported revenue of $5.1M (up 70%) yet a larger $7.8M net loss. The company raised $2.25M in a private placement and announced Nevada insurer network expansion with an estimated $4.0M in annualized savings. Today’s debt-to-equity exchange proposal directly addresses the previously highlighted leverage and Nasdaq equity deficiency.
Key Terms
debt-to-equity exchange financial
perpetual, nonconvertible preferred stock financial
common stock financial
equity financings financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
LITTLETON, Colo., June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), today announced that it has entered into a binding agreement with its senior, secured lender, Streeterville Capital, LLC (Streeterville) to exchange up to
In addition, the agreement includes commitments from Streeterville to suspend any calls for repayments of its debt and any sales of Company securities for 90 and 60 days, respectively, from the date the debt-to-equity exchange becomes effective.
In June 2025, Vivos completed the acquisition of the operating assets of The Sleep Center of Nevada (SCN), the largest operator of medical sleep centers in Nevada, marking the Company’s first major acquisition of a sleep testing center and associated medical sleep practice. The transaction, supported by debt financing from Streeterville and an equity investment from an affiliate of existing Vivos investor, New Seneca Partners, transformed the Company’s business model and its revenue and earnings potential.
The debt-to-equity exchange will be supported by, and is contingent on the completion of one or more qualifying equity financings on terms acceptable to the Company. There can be no assurance that any such financing will be completed, that the conditions to Streeterville’s exchange will be satisfied, or that any debt will ultimately be exchanged as contemplated.
The conversion of Streeterville’s debt into preferred and common stock, combined with the contemplated equity raise, is intended to improve the Company’s stockholders’ equity and advance its stockholders’ equity remediation plan to comply with Nasdaq’s listing standards. The transactions would, if consummated, also lower the Company’s debt service obligations, including suspending them for 90 days, which is expected to assist the Company’s cash flows and support liquidity.
This press release is being issued for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any securities offering, if undertaken, will be made only pursuant to applicable securities laws and definitive offering documents.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children.
OSA affects over 1 billion people worldwide, yet
Founded in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.
Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.
For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, and statements of the Company’s management and third parties (including Seneca) made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “aim,” “goal” and derivations of such words and similar expressions about the future are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the actual benefits of the debt restructuring, potential equity raise, the Company’s new model described herein and actual revenue and cash flow results) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to raise the required new equity timely or in sufficient amounts, which would cause the commitment debt-to-equity exchange to become null and void; (ii) the risk that Vivos may be unable benefit fully or at all from the transactions discussed herein, even if they are consummated, (iii) the risk that Vivos may be unable to implement revenue, sales and marketing strategies and other strategies that increase revenues, (iv) the risk that some patients may not achieve the desired results from using Vivos products, (v) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (vi) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all, or maintain its Nasdaq listing due to, among other things, a deficiency in its stockholders’ equity; (vii) market and other conditions, and (viii) other risk factors described in Vivos’ filings with the SEC. Vivos’ filings can be obtained free of charge at https://vivos.com/investors/sec-filings/. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Vivos Investor Relations and Media Contact:
Jennifer Hauser
Investor Relations Contact
investors@vivoslife.com
